Eurosin Capital have served as the sole financial advisor on this exciting transaction

[2025-01-27]

Congratulations to OncoZenge AB & Yangtian Bio-Pharmaceutical on successfully signing the strategic investment agreement for the financing of the BupiZenge Phase III studies.